Skip navigation
PR Newswire

Soligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials

PRINCETON, N.J., Jan. 25, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter...